Voyager Therapeutics, a clinical-stage developer of gene therapies for CNS diseases, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The Cambridge, MA-based company, which was founded in 2013 and booked $7 million in collaboration revenue for the 12 months ended June 30, 2015, plans to list on the Nasdaq under the symbol VYGR. Voyager Therapeutics initially filed confidentially on 6/19/2015. Cowen & Company and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
